BrIDGs Program Goals

The high cost of translating therapeutic discoveries into clinically available agents can deter the development of promising therapies. Researchers may partner with private-sector entities to advance projects with significant commercial potential, but high-risk ideas or therapies for uncommon disorders frequently do not attract investors.

When private-sector resources are limited, BrIDGs research and development expertise and services can help researchers bridge the gap between the pre-clinical and clinical stages of therapeutic development. This support enables continued evaluation of agents that may improve the standard of care for patients with a variety of diseases and disorders.